Clinical trials: Blasts Under 15 Percent of Peripheral Blood White Cells

Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

• Terminated
• Age: 18 years and older
• Phase 2
• Results posted

This phase II trial studies how well bosutinib works in treating patients with chronic myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure.

Conditions

Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30 Percent of Bone Marrow Nucleated Cells, Blasts Under 30 Percent of Peripheral Blood White Cells

Trial name

NCT02906696

Testing

Bosutinib, Laboratory Biomarker Analysis

Where

United States

Volunteers

8 people

Sponsor

M.D. Anderson Cancer Center